Bonesupport Holding AB (publ)

OM:BONEX 주식 리포트

시가총액: SEK 14.9b

Bonesupport Holding 경영진

경영진 기준 점검 3/4

Bonesupport Holding CEO는 Torbjorn Skold, Sep2025 에 임명되었습니다 의 임기는 1년 미만입니다. 총 연간 보상은 SEK4.12M, 27.8% 급여 및 72.2% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 SEK3.40M 가치에 해당하는 회사 주식의 0.023% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 5.9 년과 4 년입니다.

핵심 정보

Torbjorn Skold

최고경영자

SEK 4.1m

총 보수

CEO 급여 비율27.77%
CEO 재임 기간less than a year
CEO 지분 보유율0.02%
경영진 평균 재임 기간5.9yrs
이사회 평균 재임 기간4yrs

최근 경영진 업데이트

Recent updates

Bonesupport Holding AB (publ) Just Missed Earnings - But Analysts Have Updated Their Models

Apr 25
Bonesupport Holding AB (publ) Just Missed Earnings - But Analysts Have Updated Their Models

BONEX: Clinical Pilot Infection Outcomes Will Support Future Upside Potential

Analysts have raised their price target for Bonesupport Holding by about SEK 10.60 to SEK 377.17, citing updated assumptions that include a slightly higher discount rate, adjusted revenue growth expectations, a revised profit margin outlook, and a lower future P/E multiple. What's in the News Bonesupport Holding announced the first publication of a US clinical pilot study on the surgical technique and outcomes of CERAMENT G in trauma.

BONEX: Clinical Pilot Outcomes And 2026 Sales Outlook Will Support Future Upside Potential

Analysts have revised their price target on Bonesupport Holding to SEK 366.6. The update reflects an unchanged fair value along with adjusted assumptions for the discount rate, revenue growth, profit margin and future P/E. What's in the News Publication of a US clinical pilot study in OTA International highlighting surgical technique and outcomes for CERAMENT G in trauma cases, providing practical, real world guidance for clinicians considering the product in fracture related infections and osteomyelitis (Key Developments).

BONEX: Clinical Pilot Outcomes And 2025 Guidance Will Support Future Upside Potential

Analysts have kept their SEK price target for Bonesupport Holding unchanged at SEK 366.60, citing broadly consistent assumptions on discount rate, revenue growth, profit margin and future P/E. Together, these factors support a steady valuation view.

Slow Trauma Center Adoption And Regulatory Hurdles Will Eventually Support A Healthier Business Mix

Catalysts About Bonesupport Holding Bonesupport Holding develops and sells CERAMENT bone void fillers, including antibiotic eluting products used to treat complex bone infections and defects. What are the underlying business or industry changes driving this perspective?

BONEX: Clinical Pilot Results And Strong Guidance Will Support Long-Term Upside Potential

Analysts have trimmed their price target on Bonesupport Holding by SEK 4 to SEK 366.6. This reflects updated assumptions around discount rates, revenue growth and profitability, while keeping future P/E expectations broadly in line with previous views. What's in the News Bonesupport announced the first publication of a US clinical pilot study on the surgical technique and outcomes of CERAMENT G in trauma, giving clinicians practical, real world insights into its use in trauma cases.

US Trauma Expansion And New Surgical Uses Will Transform This Bone Regeneration Specialist

Catalysts About Bonesupport Holding Bonesupport Holding develops and sells CERAMENT bone void fillers, including antibiotic eluting products such as CERAMENT G and CERAMENT V, for use in complex bone infections and orthopedic procedures. What are the underlying business or industry changes driving this perspective?

BONEX: De Novo Shift Will Support Long Term Upside Potential

Analysts have slightly trimmed their fair value estimate for Bonesupport Holding to SEK370.6, from SEK374.6, reflecting minor adjustments to the discount rate, revenue growth, profit margin and future P/E assumptions, while keeping the overall thesis broadly intact. What's in the News Bonesupport issued earnings guidance for Q4 2025, with net sales expected at 313 MSEK at constant exchange rates, based on company guidance for that period (company guidance).

Is There An Opportunity With Bonesupport Holding AB (publ)'s (STO:BONEX) 43% Undervaluation?

Feb 12
Is There An Opportunity With Bonesupport Holding AB (publ)'s (STO:BONEX) 43% Undervaluation?

BONEX: De Novo Pathway Shift Will Support Long Term Upside Potential

Analysts have kept their fair value estimate for Bonesupport Holding steady at SEK374.60 per share. The latest price target update mainly reflects small technical tweaks to the discount rate and future P/E assumptions rather than a shift in the core outlook.

BONEX: De Novo Review Shift Will Support Long Term Upside Potential

Analysts have trimmed their price target for Bonesupport Holding to SEK 374.60 from SEK 391.20, citing slightly lower assumptions for revenue growth and profit margins, along with a higher future P/E multiple. What's in the News Bonesupport Holding issued earnings guidance for the fourth quarter of 2025 with net sales expected at SEK 313 M, based on constant exchange rates (Corporate guidance).

BONEX: De Novo Pathway Shift Will Support Long Term Upside Potential

Analysts have kept their fair value estimate for Bonesupport Holding steady at SEK391.20, with only minor tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions. This suggests their overall view on the company’s long term potential is essentially unchanged.

BONEX: De Novo Pathway Shift Will Support Strong Future Market Position

Analysts have modestly raised their price target on Bonesupport Holding, citing a slightly lower discount rate and improved visibility into sustaining approximately 38 percent revenue growth and robust 31 percent profit margins. Together, these factors support a fair value of SEK 391.20 per share.

BONEX: Hip Infection Study Success Will Drive Stronger Future Clinical And Market Position

Analysts have modestly raised their price target on Bonesupport Holding to SEK 391.2 per share from SEK 391.2 per share, reflecting largely unchanged long term assumptions on the discount rate, revenue growth, profit margins and future valuation multiples. What's in the News Positive top line data from the CeraHip clinical study show that CERAMENT G enabled successful single stage revision surgery for periprosthetic joint infection of the hip, with no re infections reported over 24 months of follow up (Key Developments).

BONEX: Positive Study Results Will Support Improvements In Hip Infection Outcomes

Analysts have adjusted their price target for Bonesupport Holding, maintaining it at SEK 391.20. Recent evaluations indicate steady expectations in light of updated discount rates and continued confidence in the company's growth and profitability outlook.

Bonesupport Holding AB (publ) (STO:BONEX) May Have Run Too Fast Too Soon With Recent 25% Price Plummet

Nov 22
Bonesupport Holding AB (publ) (STO:BONEX) May Have Run Too Fast Too Soon With Recent 25% Price Plummet

BONEX: Clinical Study Results Will Drive Long-Term Patient Outcome Improvements

Bonesupport Holding's analyst price target has been updated downward from SEK 401.80 to SEK 391.20, as analysts factor in slightly softer revenue growth forecasts and a higher discount rate. What's in the News Bonesupport announced positive results from a clinical study showing significantly improved patient-reported outcomes for CERAMENT G in single-stage revision surgery for periprosthetic joint infection of the hip (Key Developments).

Bonesupport Holding AB (publ) Just Missed Earnings - But Analysts Have Updated Their Models

Oct 28
Bonesupport Holding AB (publ) Just Missed Earnings - But Analysts Have Updated Their Models

Positive Clinical Results And US Launch Will Drive Future Success

Analysts have revised their price target for Bonesupport Holding from SEK 419.75 to SEK 401.80. This change reflects adjustments to growth and profitability assumptions.

Bonesupport Holding AB (publ)'s (STO:BONEX) Shares May Have Run Too Fast Too Soon

Aug 25
Bonesupport Holding AB (publ)'s (STO:BONEX) Shares May Have Run Too Fast Too Soon

Bonesupport Holding's (STO:BONEX) Soft Earnings Are Actually Better Than They Appear

Jul 23
Bonesupport Holding's (STO:BONEX) Soft Earnings Are Actually Better Than They Appear

Bonesupport Holding AB (publ)'s (STO:BONEX) Intrinsic Value Is Potentially 80% Above Its Share Price

Jun 28
Bonesupport Holding AB (publ)'s (STO:BONEX) Intrinsic Value Is Potentially 80% Above Its Share Price

Analyst Estimates: Here's What Brokers Think Of Bonesupport Holding AB (publ) (STO:BONEX) After Its First-Quarter Report

Apr 28
Analyst Estimates: Here's What Brokers Think Of Bonesupport Holding AB (publ) (STO:BONEX) After Its First-Quarter Report
User avatar

CERAMENT G's US Launch And CERAMENT V's FDA Submission Will Expand Global Presence

CERAMENT G's rapid U.S. penetration addresses a significant market need, likely causing notable revenue growth due to its strong clinical backing.

kr445 - That's What Analysts Think Bonesupport Holding AB (publ) (STO:BONEX) Is Worth After These Results

Mar 01
kr445 - That's What Analysts Think Bonesupport Holding AB (publ) (STO:BONEX) Is Worth After These Results

Earnings Troubles May Signal Larger Issues for Bonesupport Holding (STO:BONEX) Shareholders

Oct 31
Earnings Troubles May Signal Larger Issues for Bonesupport Holding (STO:BONEX) Shareholders

CEO 보수 분석

Torbjorn Skold의 보수는 Bonesupport Holding의 수익에 비해 어떻게 변했나요?
날짜총 보수급여회사 수익
Mar 31 2026n/an/a

SEK 185m

Dec 31 2025SEK 4mSEK 1m

SEK 142m

보상 대 시장: Torbjorn의 총 보수(USD444.01K)는 Swedish 시장에서 비슷한 규모 기업의 평균(USD1.29M)보다 낮습니다.

보상과 수익: Torbjorn의 보상을 회사 실적과 비교하기에 데이터가 부족합니다.

CEO

Torbjorn Skold (48 yo)

less than a year
재임 기간
SEK 4,123,000
보수

Mr. Torbjorn Skold serves as Member of the Supervisory Board at aap Implantate AG since August 15, 2024. He served as President and Member of Management Board at Stille AB since March 2023 until 2025 and a...

리더십 팀

이름직위재임 기간보수지분
Torbjorn Skold
Chief Executive Officerless than a yearSEK 4.12m0.023%
SEK 3.4m
Håkan Johansson
Chief Financial Officer7.5yrsSEK 3.01m0.11%
SEK 15.9m
Michael Mortensen
Executive Vice President of Global R&D and Operations4.4yrs데이터 없음0.038%
SEK 5.6m
Annelie Vikner
Executive Vice President of Global Marketing3.3yrs데이터 없음0.019%
SEK 2.8m
Helena Brandt
Executive Vice President of Human Resources8.6yrs데이터 없음0.024%
SEK 3.6m
Michael Diefenbeck
Executive VP of Medical & Clinical Affairs and Chief Medical Officer9.1yrs데이터 없음0.16%
SEK 24.4m
Fergus MacLeod
GM & Executive VP of Commercial Operations of EUROW6.5yrs데이터 없음0.028%
SEK 4.2m
Michael Roth
GM & Executive VP of Commercial Operations of US5.9yrs데이터 없음0.048%
SEK 7.2m
Anna Stegmark
Executive Vice President of Quality Management & Regulatory Affairs1.8yrs데이터 없음0.0038%
SEK 565.1k
5.9yrs
평균 재임 기간
54yo
평균 나이

경험이 풍부한 관리: BONEX의 경영진은 노련하고 경험이 풍부합니다(평균 재임 5.9 년).

이사회 구성원

이름직위재임 기간보수지분
Björn Odlander
Director16.3yrsSEK 568.00k0.41%
SEK 60.4m
Lennart Johansson
Independent Chairman of the Board9.3yrsSEK 1.28m0%
SEK 0
Jens Viebke
Director1yrSEK 329.00k0.0024%
SEK 362.9k
Christine Rankin
Independent Director4yrsSEK 854.00k0.0042%
SEK 627.6k
Mary O'Connor
Independent Director4yrsSEK 585.00k0.041%
SEK 6.1m
4.0yrs
평균 재임 기간
67yo
평균 나이

경험이 풍부한 이사회: BONEX의 이사회는 경험이 있음으로 간주됩니다(평균 재임 4 년).

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/05/04 01:50
종가2026/05/04 00:00
수익2026/03/31
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Bonesupport Holding AB (publ)는 8명의 분석가가 다루고 있습니다. 이 중 6명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
null nullABG Sundal Collier
Erik CasselDanske Bank
Kristofer Liljeberg-SvenssonDNB Carnegie